HGP0816

DRUG4 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

HealthyHyperlipidemiaHyperlipidemiasHypertensionPrimary Hypercholesterolemia

Phase 1

Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816

CompletedNCT02554136

Hanmi Pharmaceutical Company LimitedHealthy

Start: 2015-07-31End: 2015-08-31Updated: 2015-09-18

Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers

CompletedNCT02941848

Hanmi Pharmaceutical Company LimitedPrimary Hypercholesterolemia

Start: 2014-11-30End: 2015-01-31Updated: 2016-10-21

Phase 3

Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD

Hanmi Pharmaceutical Company LimitedHyperlipidemias

Start: 2014-10-31End: 2016-02-29Target: 270Updated: 2015-09-16

Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

CompletedNCT02899455

Hanmi Pharmaceutical Company LimitedHyperlipidemia, Hypertension

Start: 2014-07-31End: 2016-06-30Updated: 2016-10-20

Related Papers

A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia

Clinical Therapeutics2017-11-1422 citations

Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects.

2017-08-1015 citations